Similar to the U.S. Vaccine Adverse Events Reporting System (VAERS), the MHRA describes the purpose of its Yellow Card system as providing “an early warning that the safety of a medicine or a medical device may require further investigation.”
The report, signed by Evidence-based Medicine Consultancy Ltd and EbMC Squared CiC Director Dr. Tess Lawrie (MBBCh, PhD), says: “we have searched the Yellow Card reports using pathology-specific key words to group the data according to the following five [sic] broad, clinically relevant categories:
Bleeding, Clotting and Ischaemic ADRs
Immune System ADRs
‘Pain’ ADRs
Neurological ADRs
ADRs involving loss of Sight, Hearing, Speech or Smell
Pregnancy ADRs”
The report goes on to say: “We are aware of the limitations of pharmacovigilance data and understand that information on reported Adverse Drug Reactions should not be interpreted as meaning that the medicine in question generally causes the observed effect or is unsafe to use. We are sharing this preliminary report due to the urgent need to communicate information that should lead to cessation of the vaccination roll out while a full investigation is conducted. According to the recent paper by Seneff and Nigh, potential acute and long-term pathologies include:
Pathogenic priming, multisystem inflammatory disease and autoimmunity
Allergic reactions and anaphylaxis
Antibody dependent enhancement
Activation of latent viral infections
Neurodegeneration and prion diseases
Emergence of novel variants of SARSCoV2
Integration of the spike protein gene into the human DNA
(...)
